Progress in Cardiovascular Diseases
Volume 53, Issue 1 , Pages 68-78 , July 2010

The Framingham Heart Study's Impact on Global Risk Assessment

  • Asaf Bitton

      Affiliations

    • Division of General Medicine, Brigham and Women's Hospital, Boston, MA, USA
    • Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    • ,
  • Thomas Gaziano

      Affiliations

    • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA
    • Harvard Medical School, Boston, MA, USA
    • Department of Health Policy and Management, Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    • Corresponding Author InformationAddress reprint requests to Thomas A. Gaziano, MD, MSc, Associate Physician, Division of Cardiovascular Medicine, Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115.

References 

  1. Bruenn HG. In: Clinical notes on the illness and death of President Franklin D. Roosevelt. Annals of internal medicine. American College of Physicians; 1970;p. 579–591
  2. Reches A. Transparency with respect to the health of political leaders. Isr Med Assoc J. 2006;8:751–753
  3. Barach AL. Franklin Roosevelt's illness. Effect on course of history. N Y State J Med. 1977;77:2154–2157
  4. White PD. Heart disease. 2nd ed. New York: Macmillan; 1937;
  5. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41:279–281
  6. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50
  7. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298
  8. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probality of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318
  9. Giampaoli S, Palmieri L, Mattiello A, et al. Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases. Nutr Metab Cardiovasc Dis. 2005;15:79–85
  10. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ. 2000;320:659–661
  11. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis. 1967;20:511–524
  12. American Heart Association . Committee on Reduction of Risk of Heart and Stroke. Coronary risk handbook: estimating risk of coronary heart disease in daily practice/[prepared under the supervision of the American Heart Association, Committee on Reduction of Risk of Heart Attack and Stroke]. New York: American Heart Association; 1973;
  13. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46–51
  14. Brittain E. Probability of coronary heart disease developing. West J Med. 1982;136:86–89
  15. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  16. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753
  17. Anonymous . Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255–261
  18. Thomsen T. HeartScore: a new Web-based approach to European cardiovascular disease risk management. Eur J Cardiovasc Prev Rehabil. 2005;12:424–426
  19. Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. [see comment][erratum appears in BMJ 2000 May 27;320(7247):1436] BMJ. 2000;320:680–685
  20. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. [see comment] Circulation. 2002;106:3143–3421
  21. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709–710
  22. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053
  23. WHO . Prevention of cardiovascular disease. Guidelines for the assessment and management of total cardiovascular risk. Geneva: World Health Organization; 2007;
  24. Gori A, Bandera A, Marchetti G, et al. Spoligotyping and Mycobacterium tuberculosis. Emerg Infect Dis. 2005;11:1242–1248
  25. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112:3547–3553
  26. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–315
  27. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003
  28. Ferrario M, Chiodini P, Chambless LE, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34:413–421
  29. Woodward M, Brindle P, Tunstall-Pedoe H for the SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172–176
  30. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136
  31. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–1482
  32. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–619
  33. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243–22514p following 2251
  34. U.S. Department of Health and Human Services (DHHS) . National Center for Health Statistics. First National Health and Nutrition Examination Survey (NHANES I). Hyattsville, MD: Centers for Disease Control and Prevention; 1971-1975;
  35. Gaziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371:923–931
  36. D'Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–187
  37. Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens. 2002;20:1973–1980
  38. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327:1267
  39. Liu J, Hong Y, D'Agostino RB, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004;291:2591–2599
  40. Haq IU, Jackson PR, Yeo WW, et al. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet. 1995;346:1467–1471
  41. Wallis EJ, Ramsay LE, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ. 2000;320:671–676
  42. Anderson K, Wilson P, Odell P, et al. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362
  43. Milne R, Gamble G, Whitlock G, et al. Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level. N Z Med J. 2003;116:U662
  44. Haq IU, Ramsay LE, Jackson PR, et al. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM. 1999;92:379–385
  45. Ulmer H, Kollerits B, Kelleher C, et al. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women. Eur J Cardiovasc Prev Rehabil. 2005;12:433–441
  46. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639
  47. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2571
  48. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139–185
  49. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601–1610
  50. National Health Committee . Guidelines for the management of mildly raised blood pressure in New Zealand. Wellington, New Zealand: Core Services Committee, Ministry of Health; 1995;
  51. Lenz M, Muhlhauser I. Cardiovascular risk assessment for informed decision making. Validity of prediction tools. Med Klin (Munich). 2004;99:651–661
  52. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol. 2009;54:1209–1227
  53. Neuhauser HK, Ellert U, Kurth BM. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. Eur J Cardiovasc Prev Rehabil. 2005;12:442–450
  54. Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24:1903–1911
  55. Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114:2217–2225
  56. Hennekens CH, D'Agostino RB. Global risk assessment for cardiovascular disease and astute clinical judgement. Eur Heart J. 2003;24:1899–1900
  57. Bhopal R, Fischbacher C, Vartiainen E, et al. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf). 2005;27:93–100
  58. Hense HW, Schulte H, Löwel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24:937–945
  59. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study.. Atherosclerosis. 2005;181:93–100
  60. Stephens JW, Amber G, Vallance P, et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?. Eur J Cardiovasc Prev Rehabil. 2004;11:521–528

 Statement of Conflict of Interest: see page 76.

PII: S0033-0620(10)00085-X

doi: 10.1016/j.pcad.2010.04.001

Progress in Cardiovascular Diseases
Volume 53, Issue 1 , Pages 68-78 , July 2010

Article Tools